Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of Cerus stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $5.59, for a total transaction of $15,556.97. Following the completion of the sale, the chief financial officer now directly owns 63,608 shares in the company, valued at approximately $355,568.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

  • On Monday, December 10th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The shares were sold at an average price of $5.35, for a total transaction of $14,889.05.
  • On Monday, November 12th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The shares were sold at an average price of $5.56, for a total transaction of $15,473.48.

CERS traded down $0.08 on Friday, hitting $5.61. 414,200 shares of the company’s stock were exchanged, compared to its average volume of 740,300. Cerus Co. has a fifty-two week low of $3.77 and a fifty-two week high of $8.05. The company has a quick ratio of 3.17, a current ratio of 3.48 and a debt-to-equity ratio of 0.26. The stock has a market cap of $774.78 million, a PE ratio of -10.02 and a beta of 1.33.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Cerus had a negative net margin of 74.95% and a negative return on equity of 68.90%. The company had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $15.40 million. During the same quarter in the previous year, the company posted ($0.12) EPS. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. As a group, research analysts anticipate that Cerus Co. will post -0.43 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California Public Employees Retirement System boosted its stake in Cerus by 8.1% during the 2nd quarter. California Public Employees Retirement System now owns 127,628 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 9,528 shares during the last quarter. Teachers Advisors LLC boosted its stake in Cerus by 3.2% during the 3rd quarter. Teachers Advisors LLC now owns 312,076 shares of the biotechnology company’s stock worth $2,250,000 after purchasing an additional 9,702 shares during the last quarter. Prudential Financial Inc. boosted its stake in Cerus by 110.2% during the 3rd quarter. Prudential Financial Inc. now owns 25,403 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 13,320 shares during the last quarter. First Quadrant L P CA acquired a new stake in Cerus during the 3rd quarter worth $112,000. Finally, Essex Investment Management Co. LLC boosted its stake in Cerus by 3.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 486,972 shares of the biotechnology company’s stock worth $3,511,000 after purchasing an additional 16,175 shares during the last quarter. 60.58% of the stock is currently owned by institutional investors.

CERS has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price target on shares of Cerus in a research note on Monday, December 10th. ValuEngine cut shares of Cerus from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 12th. Zacks Investment Research raised shares of Cerus from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Wednesday, October 3rd. Finally, BidaskClub raised shares of Cerus from a “sell” rating to a “hold” rating in a research note on Saturday, December 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $9.00.

COPYRIGHT VIOLATION WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://theolympiareport.com/2019/01/11/kevin-dennis-green-sells-2783-shares-of-cerus-co-cers-stock-2.html.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Read More: Bear Market – How and Why They Occur

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.